Biogen Idec reports that the European Commission has granted marketing authorization for Plegridy (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis, the most common form of multiple sclerosis. Plegridy is dosed once every two weeks and is administered subcutaneously with the Plegridy Pen, a new ready-to-use autoinjector, or a prefilled syringe. 

Plegridy is interferon beta-1a that has been pegylated to extend its half-life to permit a less frequent dosing schedule. 

Source: Biogen Idec